{"id":"W2891836054","doi":"10.1111/bjd.17195","title":"Granulocyte–macrophage colony‐stimulating factor ( <scp>GM</scp> ‐ <scp>CSF</scp> ) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti‐ <scp>GM</scp> ‐ <scp>CSF</scp> monoclonal antibody","year":2018,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; Dermatrials Research; Probity Medical Research","funders":"Department of Medicine, University of Toronto; University of Toronto; Gentofte Hospital; Takeda Pharmaceutical Company","keywords":"Medicine; Psoriasis; Psoriasis Area and Severity Index; Placebo; Clinical endpoint; Internal medicine; Granulocyte macrophage colony-stimulating factor; Immunology; Population; Granulocyte colony-stimulating factor; Clinical trial; Monoclonal antibody; Gastroenterology; Randomized controlled trial; Antibody; Pharmacology; Cytokine; Pathology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002083101,0.0008303457,0.00188779,0.0003643809,0.0002541205,0.0007233656,0.0005265441,0.001058658,0.003569168],"category_scores_gemma":[0.001268134,0.0004047239,0.0009921986,0.0003834977,0.0007974712,0.0005132412,0.0002717843,0.001436807,0.0004471302],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004760632,"about_ca_system_score_gemma":0.0009206706,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003249336,"about_ca_topic_score_gemma":0.000889551,"domain_scores_codex":[0.9993742,0.0003357361,0.00005608023,0.00009413407,0.00008080606,0.00005903222],"domain_scores_gemma":[0.9994515,0.0001713599,0.0001630666,0.00003355964,0.0000421729,0.0001383898],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9315411,0.008187311,0.001046266,0.001862461,0.0006714323,0.00004459874,0.00004725689,0.0002443979,0.01073044,0.00009930615,0.0005637154,0.04496178],"study_design_scores_gemma":[0.9009518,0.0937612,0.002473703,0.00007060821,0.000448496,0.00004838413,0.00001311874,0.0002540775,0.001100824,0.00006827591,0.0008009555,0.000008533874],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9783804,0.01267972,0.0006765195,0.0005296569,0.0003981603,0.00553903,0.0005254265,0.0000807814,0.001190365],"genre_scores_gemma":[0.9869817,0.005496891,0.001400037,0.0005653271,0.000408193,0.00358611,0.0004248152,0.00001242865,0.00112454],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003569168,"threshold_uncertainty_score":0.01194,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02003803777489788,"score_gpt":0.2707129772893686,"score_spread":0.2506749395144707,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}